<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00927316</url>
  </required_header>
  <id_info>
    <org_study_id>RTP-A2003</org_study_id>
    <nct_id>NCT00927316</nct_id>
  </id_info>
  <brief_title>E. Coli 83972 Induced Asymptomatic Bacteriuria (ABU) in Patients With Recurrent Urinary Tract Infections (UTI)</brief_title>
  <official_title>Induced Asymptomatic E. Coli 83972 Bacteriuria in Patients With Recurrent Urinary Tract Infections and Bladder Dysfunction- is There a Protective Effect Against Recurrent Symptomatic Infections? A Blinded Placebo Controlled Cross-over Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Region Skane</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Coloplast A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Riksförbundet för Trafik, Olycksfall och Polioskadade (RTP), Sundbyberg, Sweden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Swedish Institute for Infectious Disease Control</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lund University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Region Skane</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study tests the following hypothesis: Does induced asymptomatic bacteriuria (E. coli
      83972) protect against symptomatic urinary tract infections in individuals with bladder
      emptying dysfunctions and prone to recurrent infection episodes? The study is performed using
      a double-blind randomized study protocol with a cross-over, with re-inoculations being
      patient-blinded (phase 1). After patients have fulfilled the cross-over, those who have had
      bacteriuria or placebo-periods &lt; 12 months will be subjected to additional patient blinded
      inoculations (phase 2). During the entire study (phase 1+2) the study-team and the patients
      are unaware of urine culture results.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2003</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to UTI</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of UTI</measure>
    <time_frame>During 12 months placebo or active treatment</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Urinary Tract Infection</condition>
  <arm_group>
    <arm_group_label>Active arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>E. coli 83972 bacteriuria</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Monitoring</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>E. coli 83972</intervention_name>
    <description>Active arm: Intravesical inoculation (by urethral catheterization) on three subsequent days with 30 ml E. coli 83972 (100 000 cfu/ml).
Placebo arm: Identical procedure but with saline, 30 ml.</description>
    <arm_group_label>Active arm</arm_group_label>
    <arm_group_label>Placebo arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Recurrent UTI

          -  Bladder emptying dysfunction

          -  Optimal conservative treatment incl. clean intermittent catheterization

          -  Capable of &quot;self reporting of UTI episodes&quot;

        Exclusion Criteria:

          -  Malignant disease

          -  Immunosuppression

          -  Recurrent pyelonephritis

          -  Abnormalities within upper urinary tract, including renal stones and poor kidney
             function
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fredrik Sundén, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Urology, University Hospital, 221 85 Lund</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Björn Wullt, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Dept. of Urology, Lund University Hospital, 221 85 Lund</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Urology, Lund University</name>
      <address>
        <city>Lund</city>
        <zip>SE-221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2009</study_first_submitted>
  <study_first_submitted_qc>June 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2009</study_first_posted>
  <last_update_submitted>November 9, 2009</last_update_submitted>
  <last_update_submitted_qc>November 9, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 10, 2009</last_update_posted>
  <responsible_party>
    <name_title>Fredrik Sundén, MD</name_title>
    <organization>Dept. of Urology, University Hospital, Lund, Sweden</organization>
  </responsible_party>
  <keyword>Report of Urinary Tract Infection episode</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
    <mesh_term>Bacteriuria</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

